Who are Trastuzumab Emtansine for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NERATINIB, Herceptin, Herceptin, Herceptin Hylecta®, SEVABERTINIB, Pertuzumab + trastuzumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/trastuzumab-emtansine-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Trastuzumab Emtansine for Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Trastuzumab Emtansine for Injection (Trastuzumab Emtansine for Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HER2-targeting antibody-drug conjugate. Area: Oncology.

phase 3 HER2-targeting antibody-drug conjugate HER2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Trastuzumab Emtansine for Injection (Trastuzumab Emtansine for Injection) — Shanghai Miracogen Inc.. Trastuzumab emtansine targets the HER2 protein on cancer cells and delivers a toxic payload to kill them.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Trastuzumab Emtansine for Injection TARGET	Trastuzumab Emtansine for Injection	Shanghai Miracogen Inc.	phase 3	HER2-targeting antibody-drug conjugate	HER2
NERATINIB	NERATINIB		marketed		EGFR, HER2, HER4	2017-01-01
Herceptin	trastuzumab	Roche	marketed	Antibody-drug conjugate (ADC)	HER2 receptor, subdomain IV	1998-01-01
Herceptin	Trastuzumab-Qyyp	Roche	marketed	HER2/neu receptor antagonist monoclonal antibody	HER2 (c-erbB2) proto-oncogene transmembrane receptor protein	1998-01-01
Herceptin Hylecta®	Herceptin Hylecta®	Biocon Biologics UK PLC	marketed	HER2-targeted monoclonal antibody	HER2 (human epidermal growth factor receptor 2)
SEVABERTINIB	SEVABERTINIB		marketed		HER2, EGFR
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	European Organisation for Research and Treatment of Cancer - EORTC	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HER2-targeting antibody-drug conjugate class)

GI Innovation, Inc. · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Shanghai Miracogen Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Trastuzumab Emtansine for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/trastuzumab-emtansine-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab